Parameters | Dapagliflozin group | Metformin group | P value |
---|---|---|---|
Urinary 8-OHdG/creatinine (ng/mg Cre) | |||
 Baseline | 4.3 ± 1.7 (13) | 4.4 ± 2.0 (17) | 0.88 |
 Week 16 | 4.1 ± 1.1 (13) | 5.7 ± 2.4 (17) | 0.021 |
 Change | −0.2 ± 1.6 (13) | 1.3 ± 2.3 (17) | 0.042 |
 P value within group | 0.66 | 0.031 |  |
Red blood cell (×104/μL) | |||
 Baseline | 485.6 ± 32.2 (13) | 463.5 ± 41.4 (16) | 0.12 |
 Week 16 | 507.9 ± 34.8 (12) | 453.4 ± 30.9 (15) | <0.001 |
 Change | 21.3 ± 13.2 (12) | −14.7 ± 18.1 (15) | <0.001 |
 P value within group | <0.001 | 0.007 |  |
Hemoglobin (g/dL) | |||
 Baseline | 14.9 ± 0.8 (13) | 14.0 ± 1.3 (16) | 0.036 |
 Week 16 | 15.6 ± 0.7 (12) | 14.0 ± 1.9 (15) | 0.008 |
 Change | 0.7 ± 0.4 (12) | −0.1 ± 1.3 (15) | 0.030 |
 P value within group | <0.001 | 0.67 |  |
Hematocrit (%) | |||
 Baseline | 44.1 ± 2.3 (13) | 41.7 ± 3.7 (16) | 0.048 |
 Week 16 | 46.1 ± 2.0 (12) | 40.7 ± 3.0 (15) | <0.001 |
 Change | 2.0 ± 1.3 (12) | −1.4 ± 1.7 (15) | <0.001 |
 P value within group | <0.001 | 0.007 |  |
Uric acid (mg/dL) | |||
 Baseline | 5.9 ± 0.8 (13) | 5.0 ± 0.9 (17) | 0.012 |
 Week 16 | 5.2 ± 0.6 (12) | 5.3 ± 1.0 (17) | 0.74 |
 Change | −0.7 ± 0.7 (12) | 0.3 ± 0.5 (17) | <0.001 |
 P value within group | 0.007 | 0.041 |  |